Hormonal
Metformin activates AMP-activated protein kinase (AMPK) in hepatocytes and skeletal muscle, which suppresses hepatic glucose production and increases glucose uptake, thereby lowering blood glucose and improving lipid profiles.
Metformin works by activating a cellular energy sensor (AMPK) that tells the liver to stop making glucose and muscles to take up more glucose. This happens without increasing insulin levels, which is why it doesn't cause weight gain or hypoglycemia. Understanding this mechanism highlights that its benefits are tied to cellular energy status rather than direct hormonal stimulation.
Here we report that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed. ... In metformin-treated rats, hepatic expression of SREBP-1 (and other lipogenic) mRNAs and protein is reduced; activity of the AMPK target, ACC, is also reduced. Using a novel AMPK inhibitor, we find that AMPK activation is required for metformin’s inhibitory effect on glucose production by hepatocytes. In isolated rat skeletal muscles, metformin stimulates glucose uptake coincident with AMPK activation.
Why this rating
The study uses rigorous in vitro and in vivo models with specific inhibitors (Compound C) to establish causality, but it is an animal/cell study, not a human clinical trial.
Source
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou et al. · Journal of Clinical Investigation · 2001
DOI 10.1172/jci200113505
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →